<?xml version="1.0" encoding="UTF-8"?>
<ref id="B30">
 <label>30</label>
 <element-citation publication-type="webpage">
  <person-group person-group-type="author">
   <name>
    <surname>Díez</surname>
    <given-names>JM</given-names>
   </name>
   <name>
    <surname>Romero</surname>
    <given-names>C</given-names>
   </name>
   <name>
    <surname>Gajardo</surname>
    <given-names>R</given-names>
   </name>
  </person-group>
  <source>Currently available intravenous immunoglobulin (Gamunex®-C and Flebogamma® DIF) contains antibodies reacting against SARS-CoV-2 antigens</source>
  <date-in-citation content-type="updated">Updated 2020</date-in-citation>
  <date-in-citation content-type="access-date">Accessed May 1, 2020</date-in-citation>
  <comment>
   <ext-link ext-link-type="uri" xlink:href="https://www.biorxiv.org/content/10.1101/2020.04.07.029017v2" xmlns:xlink="http://www.w3.org/1999/xlink">https://www.biorxiv.org/content/10.1101/2020.04.07.029017v2</ext-link>
  </comment>
  <pub-id pub-id-type="doi">10.1101/2020.04.07.029017</pub-id>
 </element-citation>
</ref>
